Article Text

PDF
THU0517 Invasive Fungal Infections Survey in 852 Childhood-Onset Systemic Lupus Erythematosus: A Multicenter Cohort
  1. M.F. Silva1,
  2. M.P. Ferriani1,
  3. M.T. Terreri2,
  4. R.M. Pereira3,
  5. C.S. Magalhães4,
  6. E. Bonfa3,
  7. L.M. Campos1,
  8. E.M. Okuda5,
  9. S. Appenzeller6,
  10. V.P. Ferriani7,
  11. C.M. Barbosa8,
  12. V.C. Ramos9,
  13. S. Lotufo10,
  14. C.A. Silva1
  1. 1Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo
  2. 2Pediatric Rheumatology Unit, Universidade Federal de São Paulo
  3. 3Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo
  4. 4Pediatric Rheumatology Unit, Faculdade de Medicina de Botucatu, Universidade Estadual de São Paulo, Botucatu
  5. 5Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericόrdia, Sao Paulo
  6. 6Pediatric Rheumatology Unit, Universidade Estadual de Campinas, Campinas
  7. 7Pediatric Rheumatology Unit, Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto
  8. 8Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, Sao Paulo
  9. 9Pediatric Rheumatology Unit, Pontifícia Universidade Catόlica, Sorocaba
  10. 10Pediatric Rheumatology Unit, Hospital Municipal Infantil Menino Jesus, Sao Paulo, Brazil

Abstract

Background The majority of infections in childhood-onset systemic lupus erythematosus (cSLE) patients are caused by virus and bacteria, and less frequently by opportunistic agents, such as fungi.1 However, studies evaluating solely invasive fungal infections (IFI) in cSLE patients are restricted to case reports or case series1 without any systematic evaluation of the possible associated risk factors and outcomes in pediatric lupus population.

Objectives To study the prevalence, risk factors and mortality of IFI in cSLE patients.

Methods A retrospective multicenter cohort study was performed in 852 cSLE patients from 10 Pediatric Rheumatology services of São Paulo state, Brazil. An investigator meeting was held and all participants received database training. IFI were diagnosed according to EORTC/MSG Consensus Group (proven, probable and possible).2 Demographic data, clinical, laboratorial, SLEDAI-2K, SLICC/ACR-DI, treatment and outcome were also evaluated.

Results IFI were recorded in 33/852 (3.9%) cSLE patients. Proven IFI was evidenced in 22 cSLE patients, probable IFI in 5 and possible IFI in 6. The most frequent types of IFI were candidiasis (n=20) and aspergillosis (n=9). The median of disease duration was lower (1.0 vs. 4.7 years, p<0.0001), with a higher current SLEDAI-2K [19.5 (0-44) vs. 2 (0-45), p<0.0001] and current prednisone dose [50 (10-60) vs. 10 (2-90) mg/day, p<0.0001] in patients with IFI compared to those without IFI. The frequency of death was higher in the former group (51% vs. 6%, p<0.0001). Logistic regression analysis revealed that SLEDAI-2K (OR=1.108; 95%CI=1.057-1.163; p<0.0001), current prednisone dose (OR=1.046; 95%CI=1.021-1.071; p<0.0001) and disease duration (OR=0.984; 95%CI=0.969-0.998; p=0.030) were independent risk factors for IFI (R2 Nagelkerke 0.425).

Conclusions This was the first study that characterized IFI in a large cSLE population. We identified that disease activity and glucocorticoid use were the main risk factors for these life-threatening infections, mainly in early disease course and with a high rate of fatal outcome.

References

  1. Silva MF, Ribeiro AS, Fiorot FJ, et al. Invasive aspergillosis: a severe infection in juvenile systemic lupus erythematosus patients. Lupus 2012;21:1011-6.

  2. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.